Panacea Biotec Soars 15% as Dengue Vaccine Candidate DengiAll Gets Global Push

Mumbai, June 9: Panacea Biotec share price surged as much as 15% on Tuesday after the company announced that its dengue vaccine candidate, DengiAll, has been selected for the DENSTAR project, an international initiative aimed at accelerating the vaccine’s licensure and deployment in Africa and other dengue-endemic regions. Investors cheered the development, viewing it as a significant step toward commercialisation of what could become one of the world’s few single-dose dengue vaccines.  

As of writing the stock was up 14% at Rs 631. 

DengiAll Gets International Backing 

Panacea Biotec said DengiAll will be a key part of the DENSTAR project, a four-year initiative funded under the Global Health European & Developing Countries Clinical Trials Partnership programme and supported by the European Union. The project aims to advance regulatory approvals for the vaccine in sub-Saharan Africa and facilitate its broader global use.  

The stock surged as investors cheered the global adoption of the dengue vaccine through a project. Source: NSE 

The initiative is coordinated by the Sclavo Vaccines Association and brings together a consortium of 10 partners across Europe, Africa, India, South Korea and the United States. Panacea Biotec, as the developer of DengiAll, will play a central role in the programme.  

Massive Addressable Market 

The development significantly expands the commercial opportunity for Panacea’s vaccine. According to the company and project partners, nearly 3.9 billion people globally are at risk of dengue infection, with Africa increasingly emerging as a high-priority region for disease prevention efforts.  

Investors interpreted the DENSTAR partnership as validation of DengiAll’s potential beyond India, opening the door to international markets and future licensing opportunities. The project could also help streamline regulatory pathways and accelerate access to regions where dengue cases have been rising rapidly.  

Late-Stage Clinical Development Underway 

DengiAll is currently undergoing Phase III clinical trials in India in collaboration with the Indian Council of Medical Research (ICMR). The vaccine is designed as a tetravalent formulation that targets all four dengue virus serotypes through a single-dose regimen.  

Earlier this year, Panacea Biotec completed enrolment of more than 10,300 participants in the Phase III study. Participants are being monitored over a two-year period to evaluate the vaccine’s efficacy, safety and immune response profile.  

Investors Bet on Long-Term Vaccine Opportunity 

The latest rally extends the stock’s strong momentum, with Panacea Biotec emerging as one of the market’s best-performing healthcare names in recent sessions. Investors are increasingly focusing on the company’s vaccine pipeline, particularly DengiAll, which could become India’s first indigenous single-shot dengue vaccine if approved.  

While regulatory approvals and efficacy data remain key milestones to watch, the DENSTAR partnership has strengthened expectations that Panacea Biotec could play a larger role in the global dengue vaccine market. For investors, the announcement represents another step in transforming DengiAll from a promising clinical candidate into a potentially global public-health product. 

Source

•  https://www.nseindia.com/get-quote/equity/PANACEABIO/Panacea-Biotec-Limited